Bioventus Inc. (BVS)
NASDAQ: BVS · Real-Time Price · USD
13.96
-0.17 (-1.20%)
Aug 10, 2026, 4:00 PM EDT - Market closed
Bioventus Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 27, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 29.46 | 51.24 | 41.58 | 36.96 | 30.19 | 43.93 |
Cash & Short-Term Investments | 29.46 | 51.24 | 41.58 | 36.96 | 30.19 | 43.93 |
Cash Growth | -10.49% | 23.22% | 12.49% | 22.45% | -31.29% | -49.41% |
Accounts Receivable | 138.41 | 128.3 | 127.39 | 122.79 | 136.3 | 124.96 |
Inventory | - | - | - | 91.33 | 84.77 | 61.69 |
Other Current Assets | 9.86 | 11.07 | 14.16 | 16.91 | 21.33 | 32.52 |
Total Current Assets | 177.72 | 272.84 | 275.61 | 268 | 272.58 | 263.1 |
Net Property, Plant & Equipment | 24.75 | 27.02 | 33.52 | 49.96 | 44.15 | 40.17 |
Other Intangible Assets | 351.05 | 368.42 | 404.73 | 482.35 | 639.85 | 695.19 |
Goodwill | 7.46 | 7.46 | 7.46 | 7.46 | 7.46 | 147.62 |
Other Long-Term Assets | 32.56 | 7.82 | 6.64 | 3.14 | 408.62 | 79.77 |
Total Assets | 673.35 | 683.56 | 727.96 | 810.91 | 1,373 | 1,226 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 27, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 20.2 | 10.93 | 23.69 | 23.04 | 36.7 | 16.92 |
Accrued Expenses | 109.36 | 130.24 | 135.88 | 119.8 | 111.57 | 142.35 |
Current Portion of Long-Term Debt | 18.75 | 15 | 27.34 | 27.85 | 33.06 | 18.04 |
Other Current Liabilities | 4.14 | 4.21 | 23.49 | 4.82 | 122.69 | 3.56 |
Total Current Liabilities | 152.45 | 160.38 | 210.4 | 175.5 | 304.02 | 180.86 |
Long-Term Debt | 229.7 | 278.95 | 308.29 | 367 | 385.01 | 339.64 |
Other Long-Term Liabilities | 13.78 | 15.78 | 23.67 | 47.3 | 271.4 | 171.57 |
Total Long-Term Liabilities | 243.48 | 294.73 | 331.95 | 414.3 | 656.41 | 511.21 |
Total Liabilities | 395.93 | 455.11 | 542.35 | 589.79 | 960.43 | 692.07 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 27, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 0.08 | 0.08 | 0.08 | 0.08 | 0.08 | 0.08 |
Additional Paid-in Capital | 527.93 | 520.85 | 508.09 | 494.25 | 490.58 | 465.27 |
Accumulated Other Comprehensive Income | -1.33 | -1.9 | -2.57 | 0.79 | -0.11 | 0.18 |
Retained Earnings | -298.38 | -334.93 | -357.66 | -321.54 | -165.31 | -6.6 |
Total Common Shareholders' Equity | 228.31 | 184.11 | 147.94 | 173.59 | 325.24 | 458.92 |
Minority Interest | 49.11 | 44.34 | 37.66 | 47.53 | 86.98 | 74.87 |
Shareholders' Equity | 277.41 | 228.45 | 185.6 | 221.12 | 412.22 | 533.79 |
Total Liabilities & Equity | 673.35 | 683.56 | 727.96 | 810.91 | 1,373 | 1,226 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 27, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 248.45 | 293.95 | 335.63 | 394.85 | 418.07 | 357.68 |
Net Cash (Debt) | -219 | -242.71 | -294.05 | -357.88 | -387.88 | -313.75 |
Net Cash Growth | - | - | - | - | - | - |
Net Cash Per Share | -3.14 | -3.52 | -4.55 | -5.71 | -6.32 | -6.90 |
Book Value | 228.31 | 184.11 | 147.94 | 173.59 | 325.24 | 458.92 |
Book Value Per Share | 3.27 | 2.67 | 2.29 | 2.77 | 5.30 | 10.09 |
Tangible Book Value | -130.2 | -191.78 | -264.25 | -316.22 | -322.08 | -383.89 |
Tangible Book Value Per Share | -1.87 | -2.78 | -4.09 | -5.05 | -5.25 | -8.44 |